|Application ||WB, E|
|Calculated MW||35808 Da|
|Antigen Region||271-298 aa|
|Other Names||Galectin-8, Gal-8, Po66 carbohydrate-binding protein, Po66-CBP, Prostate carcinoma tumor antigen 1, PCTA-1, LGALS8|
|Target/Specificity||This LGALS8 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 271-298 amino acids from the C-terminal region of human LGALS8.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||LGALS8 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Lectin with a marked preference for 3'-O-sialylated and 3'-O-sulfated glycans.|
|Tissue Location||Ubiquitous. Selective expression by prostate carcinomas versus normal prostate and benign prostatic hypertrophy|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a member of the galectin family. Galectins are beta-galactoside-binding animal lectins with conserved carbohydrate recognition domains. The galectins have been implicated in many essential functions including development, differentiation, cell-cell adhesion, cell-matrix interaction, growth regulation, apoptosis, and RNA splicing. This gene is widely expressed in tumoral tissues and seems to be involved in integrin-like cell interactions. Alternatively spliced transcript variants encoding different isoforms have been identified.
Cludts, S., et al. Anticancer Res. 29(12):4933-4940(2009)
Cueni, L.N., et al. Exp. Cell Res. 315(10):1715-1723(2009)
Yoshida, H., et al. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 65 (PT 5), 512-514 (2009) :
Massardo, L., et al. Lupus 18(6):539-546(2009)
Savin, S., et al. Med. Oncol. 26(3):314-318(2009)
If you have any additional inquiries please email technical services at email@example.com.